Insider Purchases: Inside the Buy
Tag: BHVN
Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel
Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.
Biohaven (BHVN), Voxx (VOXX), Asana (ASAN), and Carnival (CUK, CCL) Lead Insider Purchases the Week of 10/9/2023
Biohaven (BHVN), Voxx (VOXX), Asana (ASAN), and Carnival (CUK, CCL) constituted some of the top insider purchases the Week of 10/9/2023. CEO Vlad Coric, an astute biotech entrepreneur and investor (you can read about him here) bought $10 million worth of stock of BHVN at $22.00 a share, as did director John Childs, on 10/5. After Pfizer spent $11.6 billion to buy Biohaven's migraine treatment assets, including an already approved drug, the firm's operations focus on treatments for epilepsy, spinal muscular atrophy, and a protein degradation program with multiple potential uses. Steven Downing, Director, bought over $15 million worth of shares in the auto and consumer electronics supplier Voxx International Corp. (VOXX). The stock actually rallied more than 20% on 10/11 after Gentex Corp....